Epicrispr Biotechnologies CEO Amber Salzman, Ph.D. offers up four imperatives for industry leaders working to develop ...

Life sciences organizations face challenges spanning culture, leadership, infrastructure, and skills to implement FAIR data ...

The N=1 frontier isnt just about helping the rarest patients, its about building the infrastructure for medicines future, write experts at Uncommon Cures.

In the rapidly evolving landscape of pharmaceutical development, AI promises to revolutionize the entire drug discovery and development process, impacting target discovery, clinical trial design, site ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

A real Renaissance man. That’s how some might describe Robert Hariri, M.D., Ph.D. Why? Well, in addition to being a jet aviator, a surgeon, a biomedical scientist, and a successful serial entrepreneur ...

The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions. Those ...

In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.

In a complex global and competitive world, formulating a plan without testing it against likely external reactions is the equivalent of walking into a battlefield without the right weapons or a plan ...

A-Alpha Bio CEO and AlphaSeq platform co-inventor David Younger found himself frustrated by academic science’s seeming tendency to “do science for the sake of science,” which he acknowledges is ...